CYTK Cytokinetics, Incorporated - Common Stock
$76.68
가격 · 8월 19, 2026
기준 재무 정보 8월 6, 2026
52주 범위
$35–$88
78% of range
애널리스트 평점
BUY
28 analysts
목표 주가
$110
+43% upside
P/E (TTM)
-11.7
ROE
152.7%
순이익률
-891.6%
Cytokinetics, Incorporated - Common Stock 정보 위키백과 회사 개요
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
더 보기
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
History
Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.
Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.
In 2004 the company completed its initial public offering (IPO).
In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.
In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.
Products
Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure. In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021, and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil.
Reldesemtiv (previously known as CK-2127107) is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS.
Aficamten (previously known as CK-3773274) is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
CYTK 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
가격
$76.67
시가총액
$9.43B
P/E (TTM)
-11.7
EPS (TTM)
$-6.54
매출 (TTM)
$88M
배당 수익률
—
ROE
152.7%
부채/자본
-0.4
52주 범위
$35 – $88
CYTK 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
Configure
10년 성과 매출, 순이익, 마진 및 EPS 추세
매출 및 순이익
$88M
2016-12-31
→
2025-12-31
EPS
$-6.54
2016-12-31
→
2025-12-31
잉여현금흐름
$-535M
2016-12-31
→
2025-12-31
마진
-891.6%
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
지표
5년 추세
CYTK
동종업계 중앙값
P/E (TTM)
-11.7
28.5
P/S (TTM)
107.1
20.1
P/B
-14.3
12.9
EV / EBITDA
-15.9
—
Price / FCF (주가 / FCF)
-17.6
—
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
지표
5년 추세
CYTK
동종업계 중앙값
Operating Margin (영업이익률)
-695.4%
—
Net Profit Margin (순이익률)
-891.6%
-48.4%
ROA
-55.5%
-28.4%
ROE
152.7%
-49.2%
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
지표
5년 추세
CYTK
동종업계 중앙값
Debt / Equity (부채 / 자기자본 비율)
-0.4
—
Current Ratio (유동비율)
4.5
5.0
Quick Ratio (당좌 비율)
0.7
—
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
지표
5년 추세
CYTK
동종업계 중앙값
Revenue YoY (매출 YoY)
376.6%
—
Revenue CAGR 3Y (매출 CAGR 3년)
-2.4%
—
Revenue CAGR 5Y (매출 CAGR 5년)
9.5%
—
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
지표
5년 추세
CYTK
동종업계 중앙값
CYTK 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
매수
28 명의 애널리스트
- 적극 매수 6 21.4%
- 매수 19 67.9%
- 보유 3 10.7%
- 매도 0 0.0%
- 적극 매도 0 0.0%
12개월 목표 주가
20 명의 애널리스트 · 2026-08-18
중앙값
$107.50
← 모든 목표가 하회
$76.67
저가
$85.00
고가
$146.00
중앙값 목표
$107.50
+40.2%
평균 목표
$109.90
+43.3%
실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
평균 서프라이즈
-0.08%
| 기간 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|
| 2026년 6월 30일 | $-1.50 | $-1.67 | 0.17% |
| 2026년 3월 31일 | $-1.67 | $-1.69 | 0.02% |
| 2025년 12월 31일 | $-1.50 | $-1.49 | -0.01% |
| 2025년 9월 30일 | $-2.55 | $-1.61 | -0.94% |
| 2025년 6월 30일 | $-1.12 | $-1.41 | 0.28% |
| 2025년 3월 31일 | $-1.39 | $-1.41 | 0.02% |
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
| SMMT | $13.56B | -12.1 | — | — | -235.1% | — |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | — |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | — |
| APGE | $5.16B | -17.9 | — | — | — | — |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | — |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 16
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| R&D Expense | $416M | $339M | $330M | $241M | $160M | $97M | $86M | $89M | $90M | $60M | $46M | $44M | |
| SG&A Expense | $284M | $215M | $174M | $178M | $97M | $53M | $40M | $31M | $36M | $28M | $20M | $17M | |
| Operating Expenses | $700M | $555M | $504M | $419M | $257M | $150M | $126M | $120M | $127M | $88M | $66M | $62M | |
| Operating Income | $-612M | $-536M | $-496M | $-324M | $-186M | $-94M | $-99M | $-89M | $-113M | $19M | $-37M | $-15M | |
| Interest Expense | $46M | $38M | $28M | $19M | $16M | $16M | $7M | $4M | $3M | $3M | $268.0K | $0 | |
| Interest Income | · | · | · | $11M | $1M | $5M | $4M | $4M | · | $449.0K | $156.0K | $101.0K | |
| Other Non-op | $48M | $52M | $28M | $11M | $331.0K | $5M | $5M | $4M | $3M | $464.0K | $174.0K | $108.0K | |
| Pretax Income | · | · | · | · | · | · | · | $-106M | $-128M | $16M | $-38M | $-15M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| EPS (Basic) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.41 | $-0.97 | $-0.41 | |
| EPS (Diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 | |
| Shares (Basic) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 39,943,000 | 38,814,000 | 35,709,000 | |
| Shares (Diluted) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 42,561,000 | 38,814,000 | 35,709,000 | |
| EBITDA | $-602M | $-527M | $-484M | $-318M | $-184M | $-92M | $-98M | $-88M | $-111M | $19M | $-37M | $-14M |
대차대조표 26
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $123M | $95M | $113M | $66M | $113M | $83M | $36M | $42M | $125M | $67M | $65M | $20M | |
| Receivables | $18M | $17M | $1M | $147.0K | $52M | $4M | $5M | $2M | $1M | $24.0K | · | · | |
| Inventory | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $17M | $15M | $12M | $12M | $12M | $6M | $3M | $2M | $4M | $2M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Assets | $917M | $1.11B | $628M | $795M | $536M | $474M | $234M | $208M | $274M | $159M | $113M | $131M | |
| PP&E (Net) | $79M | $66M | $69M | $80M | $73M | $13M | $5M | $3M | $4M | $4M | $2M | $2M | |
| PP&E (Gross) | $126M | $103M | $97M | $98M | $89M | $38M | $29M | $27M | $26M | $25M | $23M | $22M | |
| Accum. Depreciation | $47M | $37M | $28M | $17M | $16M | $25M | $24M | $24M | $23M | $21M | $21M | $20M | |
| Other Non-current Assets | $17M | $8M | $8M | $10M | $7M | $6M | · | $300.0K | $429.0K | $200.0K | $200.0K | $200.0K | |
| Total Assets | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Accounts Payable | $22M | $20M | $22M | $26M | $21M | $8M | $8M | $4M | $5M | $4M | $2M | $1M | |
| Accrued Liabilities | $83M | $55M | $43M | $44M | $34M | $19M | $12M | $16M | $17M | $18M | $8M | $5M | |
| Current Liabilities | $202M | $180M | $103M | $85M | $72M | $31M | $26M | $22M | $32M | $33M | $32M | $24M | |
| Capital Leases | $108M | $113M | $120M | $127M | $112M | $440.0K | $2M | $771.0K | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $186.0K | $1M | $4M | $0 | · | $771.0K | $1M | $142.0K | · | · | |
| Total Liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597M | $420M | $301M | $185M | $185M | $76M | $47M | $41M | |
| Long-term Debt | $288M | $620M | $639M | $650M | · | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Total Debt | $288M | $105M | $68M | $64M | $47M | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Common Stock | $123.0K | $118.0K | $102.0K | $94.0K | $84.0K | $70.0K | $59.0K | $55.0K | $54.0K | $41.0K | $40.0K | $39.0K | |
| Paid-in Capital | · | · | · | · | $1.45B | · | · | · | · | · | · | $589M | |
| Retained Earnings | $-3.49B | $-2.70B | $-2.11B | $-1.59B | $-1.21B | $-992M | $-865M | $-743M | $-646M | $-518M | $-535M | $-497M | |
| AOCI | $630.0K | $2M | $-10.0K | $-4M | $-869.0K | $149.0K | $679.0K | $500.0K | $343.0K | $137.0K | $149.0K | $-4.0K | |
| Stockholders' Equity | $-660M | $-135M | $-386M | $-108M | $244M | $113M | $-11M | $26M | $110M | $94M | $69M | $92M | |
| Liabilities + Equity | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Shares Outstanding | 122,943,172 | 118,209,139 | 101,637,922 | 94,833,975 | 84,799,542 | 71,015,183 | 59,172,124 | 54,717,906 | 53,960,832 | 40,646,595 | 39,581,692 | 38,659,738 |
현금 흐름 16
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $10M | $12M | $6M | $2M | $2M | $1M | $1M | $2M | $741.0K | $589.0K | $490.0K | |
| Stock-based Comp | $112M | $98M | $72M | $48M | $27M | $18M | $11M | $10M | $9M | $7M | $5M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Other Non-cash | $153M | $86M | $28M | $36M | $44M | $117M | $19M | $-6M | $15M | $13M | $37M | $-34M | |
| Operating Cash Flow | $-510M | $-396M | $-414M | $-300M | $-143M | $9M | $-91M | $-101M | $-102M | $37M | $5M | $-45M | |
| CapEx | $25M | $4M | $1M | $11M | $49M | $11M | $3M | $889.0K | $3M | $2M | $562.0K | $1M | |
| Investing Cash Flow | $17M | $-553M | $239M | $-262M | $-148M | $-197M | $-75M | $5M | $-66M | · | · | · | |
| Net Debt Issued | $-11M | $-9M | · | $-48M | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Net Stock Activity | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Financing Cash Flow | $524M | $931M | $221M | $516M | $320M | $234M | $160M | $13M | $226M | · | · | · | |
| Net Change in Cash | $30M | $-18M | $46M | $-45M | $30M | $47M | $-6M | $-83M | $58M | $2M | $45M | $57.0K | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | · | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |
| Free Cash Flow | $-535M | $-400M | $-416M | $-311M | $-191M | $-2M | $-94M | $-102M | $-105M | $35M | $4M | $-46M | |
| Levered FCF | · | · | · | · | · | · | · | $-106M | $-108M | $33M | · | $-46M |
수익성 7
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% | -130.5% | -31.4% | |
| Net Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| Pretax Margin | · | · | · | · | · | · | · | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| EBITDA Margin | -683.9% | -2851.1% | -6431.8% | -336.6% | -261.3% | -165.0% | -363.2% | -278.3% | -833.9% | 18.3% | -128.5% | -30.4% | |
| ROA | -55.5% | -53.0% | -57.2% | -41.9% | -31.3% | -30.9% | -48.6% | -42.0% | -55.0% | 11.5% | -30.2% | -13.6% | |
| ROE | 152.7% | 789.8% | 127.6% | 628.0% | -87.4% | -96.8% | 790.0% | -272.5% | -125.2% | 20.2% | -46.7% | -20.0% | |
| ROIC | · | · | · | · | · | · | · | -130.1% | -80.1% | 15.0% | -44.9% | -16.0% |
유동성 및 지급능력 5
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 | 15.2 | 9.0 | 9.4 | 8.5 | 4.8 | 3.6 | 5.5 | |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 | 2.8 | 1.6 | 2.0 | 3.9 | 2.0 | 2.1 | 0.8 | |
| Debt / Equity | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.6 | 0.3 | 0.3 | 0.2 | · | |
| LT Debt / Equity | -0.4 | -0.7 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.5 | 0.3 | 0.3 | 0.2 | · | |
| Interest Coverage | -13.4 | -14.2 | -17.5 | -16.7 | -11.3 | -5.9 | -14.9 | -23.4 | -37.6 | 6.9 | · | · |
효율성 2
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 0.2 | 0.4 | |
| Receivables Turnover | 5.1 | 2.1 | 10.5 | 3.6 | 2.5 | 11.7 | 7.3 | 18.8 | 23.5 | · | · | · |
성장률 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -2.4% | -36.0% | -48.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.5% | · | · | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM) 14
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| Net Income TTM | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| Market Cap | $7.81B | $5.56B | $8.49B | $4.35B | $3.87B | $1.48B | $628M | $346M | $440M | $494M | $414M | $310M | |
| Enterprise Value | $7.98B | $5.57B | $8.44B | $4.34B | $3.80B | $1.44B | $636M | $346M | $346M | $457M | $364M | · | |
| P/E | -9.7 | -8.9 | -15.3 | -10.6 | -16.3 | -10.5 | · | · | -3.1 | 31.2 | -10.8 | -19.5 | |
| P/S | 88.7 | 301.0 | 1126.9 | 45.9 | 54.9 | 26.4 | 23.4 | 11.0 | 32.9 | 4.6 | 14.4 | 6.6 | |
| P/B | -11.8 | -41.1 | -22.0 | -40.3 | 15.8 | 13.0 | -57.4 | 13.3 | 4.0 | 5.2 | 6.0 | 3.4 | |
| P / Tangible Book | · | · | · | · | 15.8 | 13.0 | · | · | · | · | · | · | |
| P / Cash Flow | -15.3 | -14.0 | -20.5 | -14.5 | -27.1 | 165.0 | -6.9 | -3.4 | -4.3 | 13.4 | 84.8 | -6.9 | |
| P / FCF | -14.6 | -13.9 | -20.4 | -14.0 | -20.2 | -699.7 | -6.7 | -3.4 | -4.2 | 14.0 | 95.8 | -6.7 | |
| EV / EBITDA | -13.2 | -10.6 | -17.4 | -13.6 | -20.6 | -15.6 | -6.5 | -3.9 | -3.1 | 23.5 | -9.9 | · | |
| EV / FCF | -14.9 | -13.9 | -20.3 | -14.0 | -19.9 | -682.3 | -6.8 | -3.4 | -3.3 | 12.9 | 84.1 | · | |
| EV / Revenue | 90.6 | 301.5 | 1121.0 | 45.9 | 54.0 | 25.8 | 23.7 | 11.0 | 25.9 | 4.3 | 12.7 | · | |
| Earnings Yield | -10.3% | -11.2% | -6.5% | -9.4% | -6.1% | -9.5% | · | · | -31.8% | 3.2% | -9.3% | -5.1% |
손익계산서 14
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $19M | $18M | $2M | $67M | $2M | $17M | $463.0K | $249.0K | $835.0K | $2M | $378.0K | $867.0K | $5M | $2M | $3M | |
| R&D Expense | $98M | $96M | $104M | $99M | $110M | $98M | $94M | $85M | $80M | $82M | $85M | $83M | $83M | $79M | $75M | $63M | |
| SG&A Expense | $104M | $105M | $92M | $69M | $66M | $57M | $62M | $57M | $51M | $46M | $44M | $40M | $40M | $50M | $54M | $48M | |
| Operating Expenses | $208M | $203M | $196M | $169M | $178M | $157M | $156M | $141M | $130M | $127M | $129M | $123M | $123M | $129M | $129M | $111M | |
| Operating Income | $-179M | $-184M | $-178M | $-167M | $-112M | $-156M | $-139M | $-141M | $-130M | $-126M | $-127M | $-122M | $-122M | $-124M | $-127M | $-108M | |
| Interest Expense | · | · | $14M | $11M | $11M | · | $9M | $9M | $13M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Other Non-op | $14M | $11M | $11M | $10M | $13M | $14M | $15M | $17M | $12M | $8M | $8M | $7M | $7M | $6M | $6M | $4M | |
| Net Income | $-199M | $-206M | $-183M | $-306M | $-134M | $-161M | $-150M | $-161M | $-143M | $-136M | $-137M | $-129M | $-129M | $-131M | $-137M | $-142M | |
| EPS (Basic) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| EPS (Diluted) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| Shares (Basic) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| Shares (Diluted) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| EBITDA | $-179M | $-180M | · | $-167M | $-112M | $-153M | · | $-141M | $-130M | $-124M | · | $-122M | $-122M | $-123M | · | $-108M |
대차대조표 24
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $255M | $130M | $123M | $225M | $75M | $74M | $95M | $47M | $190M | $120M | · | $100M | $69M | $102M | · | $106M | |
| Receivables | $24M | $7M | $18M | $2M | $8M | $2M | $17M | $244.0K | $0 | $834.0K | · | $2M | $985.0K | $1M | · | $2M | |
| Inventory | $380.0K | $154.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $14M | $17M | $13M | $20M | $16M | $15M | $7M | $11M | $19M | · | $20M | $20M | $16M | · | $14M | |
| Current Assets | $1.21B | $839M | $917M | $977M | $887M | $956M | $1.11B | $1.02B | $1.07B | $639M | · | $561M | $587M | $681M | · | $884M | |
| PP&E (Net) | $79M | $82M | $79M | $76M | $70M | $67M | $66M | $64M | $66M | $68M | · | $76M | $77M | $79M | · | $80M | |
| PP&E (Gross) | · | · | $126M | · | · | · | $103M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $37M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $19M | $18M | $17M | $17M | $15M | $13M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | · | |
| Total Assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Accounts Payable | $21M | $25M | $22M | $22M | $16M | $14M | $20M | $12M | $9M | $13M | · | $14M | $13M | $17M | · | $14M | |
| Accrued Liabilities | $77M | $69M | $83M | $62M | $52M | $43M | $55M | $50M | $40M | $40M | · | $33M | $31M | $36M | · | $40M | |
| Current Liabilities | $181M | $199M | $202M | $142M | $131M | $160M | $180M | $110M | $103M | $89M | · | $78M | $66M | $75M | · | $76M | |
| Capital Leases | $102M | $105M | $108M | $111M | $111M | $113M | $113M | $115M | $117M | $119M | · | $122M | $124M | $125M | · | $114M | |
| Other Non-current Liabilities | · | · | · | $2M | $2M | $3M | · | $0 | $0 | $2.0K | · | $408.0K | $625.0K | $837.0K | · | $1M | |
| Total Liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B | $1.20B | · | $1.18B | $1.11B | $1.12B | · | $1.09B | |
| Long-term Debt | $276M | $292M | $288M | $1.00B | $610M | $610M | $105M | $620M | $629M | $630M | · | · | · | · | · | · | |
| Total Debt | $276M | $292M | · | $176M | $173M | $105M | · | $105M | $104M | $68M | · | $61M | $62M | $64M | · | $64M | |
| Common Stock | $138.0K | $124.0K | $123.0K | $122.0K | $119.0K | $119.0K | $118.0K | $118.0K | $117.0K | $105.0K | · | $94.0K | $94.0K | $94.0K | · | $93.0K | |
| Retained Earnings | $-3.89B | $-3.69B | $-3.49B | $-3.30B | $-3.00B | $-2.86B | $-2.70B | $-2.55B | $-2.39B | $-2.25B | · | $-1.98B | $-1.85B | $-1.72B | · | $-1.45B | |
| AOCI | $-4M | $-2M | $630.0K | $34.0K | $-158.0K | $2M | $2M | $5M | $-1M | $-539.0K | · | $-874.0K | $-1M | $-2M | · | $-6M | |
| Stockholders' Equity | $-173M | $-827M | $-660M | $-521M | $-369M | $-266M | $-135M | $-14M | $109M | $-396M | $-386M | $-439M | $-333M | $-229M | $-108M | $-16M | |
| Liabilities + Equity | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Shares Outstanding | · | · | 122,943,172 | · | · | · | 118,209,139 | · | · | · | · | · | · | · | · | · |
현금 흐름 12
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $36M | $30M | $31M | $31M | $28M | $24M | $26M | $25M | $25M | $22M | $19M | $19M | $19M | $15M | $13M | $13M | |
| Other Non-cash | · | $27M | · | · | · | $4M | · | · | · | $-18M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-160M | $-145M | $-143M | $-108M | $-128M | $-132M | $-66M | $-102M | $-99M | $-130M | $-74M | $-96M | $-122M | $-122M | $-98M | $-84M | |
| CapEx | $4M | $6M | $6M | $9M | $4M | $6M | $1M | $701.0K | $2M | $0 | $77.0K | $220.0K | $717.0K | $402.0K | $3M | $6M | |
| Investing Cash Flow | $-507M | $145M | $-71M | $-71M | $53M | $106M | $111M | $-45M | $-652M | $33M | $-81M | $73M | $82M | $165M | $29M | $-292M | |
| Net Debt Issued | · | $-3M | · | · | · | $-3M | · | · | · | $-705.0K | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | · | · | · | $94M | · | · | · | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $94M | · | · | · | · | · | · | |
| Financing Cash Flow | $793M | $8M | $111M | $330M | $79M | $5M | $2M | $3M | $821M | $104M | $169M | $54M | $5M | $-7M | $30M | $389M | |
| Net Change in Cash | $125M | $7M | $-103M | $152M | $2M | $-21M | $48M | $-143M | $70M | $7M | $13M | $31M | $-34M | $36M | $-39M | $13M | |
| Free Cash Flow | · | $-151M | · | · | · | $-137M | · | · | · | $-130M | · | · | · | $-123M | · | · |
수익성 5
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -626.0% | -948.7% | · | -8613.4% | -167.0% | -9856.3% | · | -30410.6% | -52277.9% | -15118.0% | · | -32345.2% | -14077.2% | -2698.3% | · | -4311.8% | |
| Net Margin | -694.4% | -1064.5% | · | -15815.0% | -201.3% | -10220.1% | · | -34675.0% | -57557.4% | -16244.7% | · | -34238.6% | -14837.0% | -2846.1% | · | -5658.4% | |
| EBITDA Margin | -626.0% | -931.2% | · | -8613.4% | -167.0% | -9710.6% | · | -30410.6% | -52277.9% | -14838.8% | · | -32345.2% | -14077.2% | -2658.2% | · | -4311.8% | |
| ROA | -12.6% | -16.2% | · | -21.3% | -9.8% | -15.6% | · | -14.8% | -12.4% | -16.0% | · | -14.2% | -16.6% | -15.0% | · | -14.9% | |
| ROE | 73.3% | 37.7% | · | 114.5% | 103.3% | 48.7% | · | 70.9% | 127.6% | 43.4% | · | 56.9% | 116.1% | 232.9% | · | -122.1% |
유동성 및 지급능력 5
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 4.2 | · | 6.9 | 6.8 | 6.0 | · | 9.3 | 10.4 | 7.2 | · | 7.2 | 8.9 | 9.0 | · | 11.6 | |
| Quick Ratio | 1.5 | 0.7 | · | 1.6 | 0.6 | 0.5 | · | 0.4 | 1.9 | 1.4 | · | 1.3 | 1.1 | 1.4 | · | 1.4 | |
| Debt / Equity | -1.6 | -0.4 | · | -0.3 | -0.5 | -0.4 | · | -7.5 | 1.0 | -0.2 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| LT Debt / Equity | -1.4 | -0.3 | · | -0.3 | -0.4 | -0.3 | · | -6.7 | 0.9 | -0.1 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| Interest Coverage | · | · | · | -14.7 | -10.1 | · | · | -15.8 | -10.2 | -17.8 | · | -17.1 | -17.3 | -17.9 | · | -15.9 |
효율성 2
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.7 | 4.4 | · | 1.9 | 15.9 | 1.1 | · | 0.3 | 0.5 | 0.9 | · | 0.2 | 0.6 | 1.3 | · | 1.7 |
가치 평가 (TTM) 4
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $117M | $90M | · | $71M | $69M | $3M | · | $2M | $2M | $7M | · | $8M | $97M | $97M | · | $98M | |
| Net Income TTM | $-845M | $-808M | · | $-762M | $-600M | $-601M | · | $-569M | $-537M | $-525M | · | $-532M | $-422M | $-383M | · | $-328M | |
| P/E | -12.5 | -9.8 | · | -8.6 | -6.4 | -7.5 | · | -9.9 | -10.2 | -13.0 | · | -5.3 | -7.3 | -8.4 | · | -12.9 | |
| Earnings Yield | -8.0% | -10.2% | · | -11.6% | -15.6% | -13.3% | · | -10.1% | -9.8% | -7.7% | · | -19.0% | -13.7% | -11.9% | · | -7.7% |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 매출 | $88M | $18M | $8M | $95M | $70M |
| 영업이익률 % | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% |
| 순이익 | $-785M | $-590M | $-526M | $-389M | $-215M |
| 희석 EPS | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
대차대조표
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 부채 / 자기자본 비율 | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 |
| 유동비율 | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 |
| 당좌 비율 | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 |
현금 흐름
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 잉여현금흐름 | $-535M | $-400M | $-416M | $-311M | $-191M |
최신 뉴스 이 회사 관련 최근 헤드라인
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
📊
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
기관 투자자 (13F) 540개의 제출자 · $9.0B 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
기관 활동 — Q2 2026 대 이전 분기
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 104 (0 이전 분기 대비) | 49 (-6 이전 분기 대비) | 222 (+43 이전 분기 대비) | 112 (-32 이전 분기 대비) | +5.3M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | $571,778,157 | 6,711,799 | 6.37% | 주식 |
| STATE STREET CORP | $553,243,709 | 6,494,233 | 6.16% | 주식 |
| VANGUARD CAPITAL MANAGEMENT LLC | $521,151,103 | 6,117,515 | 5.80% | 주식 |
| WELLINGTON MANAGEMENT GROUP LLP | $509,521,049 | 5,980,996 | 5.67% | 주식 |
| Avoro Capital Advisors LLC | $425,949,915 | 4,999,999 | 4.74% | 주식 |
| FMR LLC | $375,035,430 | 4,402,341 | 4.18% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $259,207,450 | 3,042,018 | 2.89% | 주식 |
| BANK OF AMERICA CORP /DE/ | $251,706,463 | 2,954,648 | 2.80% | 주식 |
| RTW INVESTMENTS, LP | $243,814,036 | 2,862,003 | 2.72% | 주식 |
| Polar Capital Holdings Plc | $191,988,358 | 2,253,649 | 2.14% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $161,060,214 | 1,890,600 | 1.79% | 콜 옵션 |
| Capital Research Global Investors | $143,683,584 | 1,686,625 | 1.60% | 주식 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $136,597,224 | 1,603,442 | 1.52% | 주식 |
| Integral Health Asset Management, LLC | $136,304,000 | 1,600,000 | 1.52% | 주식 |
| Point72 Asset Management, L.P. | $135,257,185 | 1,587,712 | 1.51% | 주식 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $133,386,924 | 1,565,758 | 1.49% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $131,998,327 | 1,549,458 | 1.47% | 주식 |
| PRINCIPAL FINANCIAL GROUP INC | $111,435,932 | 1,308,087 | 1.24% | 주식 |
| Capital International Investors | $111,245,191 | 1,305,848 | 1.24% | 주식 |
| ARMISTICE CAPITAL, LLC | $106,487,500 | 1,250,000 | 1.19% | 콜 옵션 |
| ARMISTICE CAPITAL, LLC | $102,342,325 | 1,201,342 | 1.14% | 주식 |
| Pictet Asset Management Holding SA | $99,038,455 | 1,160,463 | 1.10% | 주식 |
| Frazier Life Sciences Management, L.P. | $98,810,092 | 1,159,879 | 1.10% | 주식 |
| Holocene Advisors, LP | $97,506,685 | 1,144,579 | 1.09% | 주식 |
| Woodline Partners LP | $93,769,315 | 1,100,708 | 1.04% | 주식 |
| NORGES BANK | $86,512,319 | 1,015,522 | 0.96% | 주식 |
| Royalty Pharma Sub-Manager, LLC | $83,519,594 | 980,392 | 0.93% | 주식 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $81,937,000 | 961,815 | 0.91% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $77,218,175 | 906,423 | 0.86% | 주식 |
| CITADEL ADVISORS LLC | $77,062,874 | 904,600 | 0.86% | 콜 옵션 |
| Melqart Asset Management (UK) Ltd | $65,385,455 | 767,525 | 0.73% | 주식 |
| Siren, L.L.C. | $64,655,121 | 758,952 | 0.72% | 주식 |
| Fisher Asset Management, LLC | $63,355,547 | 743,697 | 0.71% | 주식 |
| Foresite Capital Management IV, LLC | $60,884,867 | 714,695 | 0.68% | 주식 |
| Balyasny Asset Management L.P. | $60,599,821 | 711,349 | 0.67% | 주식 |
| Deep Track Capital, LP | $59,633,000 | 700,000 | 0.66% | 주식 |
| JANE STREET GROUP, LLC | $59,633,000 | 700,000 | 0.66% | 콜 옵션 |
| BNP PARIBAS FINANCIAL MARKETS | $58,702,470 | 689,077 | 0.65% | 주식 |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | $56,251,809 | 660,310 | 0.63% | 주식 |
| CITADEL ADVISORS LLC | $54,601,338 | 640,936 | 0.61% | 주식 |
| GOLDMAN SACHS GROUP INC | $54,053,311 | 634,503 | 0.60% | 주식 |
| Qube Research & Technologies Ltd | $48,774,257 | 572,535 | 0.54% | 주식 |
| EVENTIDE ASSET MANAGEMENT, LLC | $48,081,832 | 564,398 | 0.54% | 주식 |
| Affinity Asset Advisors, LLC | $46,854,500 | 550,000 | 0.52% | 주식 |
| First Turn Management, LLC | $44,930,228 | 527,412 | 0.50% | 주식 |
| AMERICAN CENTURY COMPANIES INC | $44,162,525 | 518,398 | 0.49% | 주식 |
| Caption Management, LLC | $43,651,356 | 512,400 | 0.49% | 콜 옵션 |
| D. E. Shaw & Co., Inc. | $40,874,247 | 479,801 | 0.46% | 주식 |
| Checkpoint Capital L.P. | $40,465,250 | 475,000 | 0.45% | 주식 |
| Hood River Capital Management LLC | $39,977,367 | 469,273 | 0.45% | 주식 |
| RP Management, LLC | $39,401,954 | 980,392 | 0.44% | 주식 |
| EMERALD ADVISERS, LLC | $39,013,272 | 457,956 | 0.43% | 주식 |
| ADAR1 Capital Management, LLC | $39,009,097 | 457,907 | 0.43% | 주식 |
| AMERIPRISE FINANCIAL INC | $38,010,006 | 446,179 | 0.42% | 주식 |
| Candriam S.C.A. | $37,708,477 | 443,066 | 0.42% | 주식 |
| MARSHALL WACE, LLP | $36,259,335 | 425,629 | 0.40% | 주식 |
| RHUMBLINE ADVISERS | $35,933,015 | 421,799 | 0.40% | 주식 |
| CITADEL ADVISORS LLC | $35,882,028 | 421,200 | 0.40% | 풋 옵션 |
| ALLIANCEBERNSTEIN L.P. | $35,327,299 | 535,993 | 0.39% | 주식 |
| GILDER GAGNON HOWE & CO LLC | $34,096,829 | 400,245 | 0.38% | 주식 |
| TD Asset Management Inc | $32,809,225 | 385,130 | 0.37% | 주식 |
| BlackRock, Inc. | $29,124,928 | 341,882 | 0.32% | 주식 |
| GSK plc | $29,001,573 | 340,434 | 0.32% | 주식 |
| TWO SIGMA INVESTMENTS, LP | $27,040,243 | 317,411 | 0.30% | 주식 |
| CITIGROUP INC | $26,852,314 | 315,205 | 0.30% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $24,671,024 | 289,600 | 0.27% | 풋 옵션 |
| Trails Edge Capital Partners, LP | $24,542,302 | 288,089 | 0.27% | 주식 |
| EMERALD MUTUAL FUND ADVISERS TRUST | $23,833,521 | 279,769 | 0.27% | 주식 |
| Polaris Capital Management, LLC | $22,737,211 | 266,900 | 0.25% | 주식 |
| SEGALL BRYANT & HAMILL, LLC | $21,899,197 | 257,063 | 0.24% | 주식 |
| Alyeska Investment Group, L.P. | $21,297,500 | 250,000 | 0.24% | 주식 |
| ExodusPoint Capital Management, LP | $21,234,374 | 249,259 | 0.24% | 주식 |
| Capital World Investors | $21,196,550 | 248,815 | 0.24% | 주식 |
| Walleye Capital LLC | $20,422,428 | 239,728 | 0.23% | 주식 |
| E. Ohman J:or Asset Management AB | $19,823,223 | 300,762 | 0.22% | 주식 |
| Sarissa Capital Management LP | $19,476,393 | 228,623 | 0.22% | 주식 |
| Swiss National Bank | $18,946,256 | 222,400 | 0.21% | 주식 |
| SPHERA FUNDS MANAGEMENT LTD. | $18,740,693 | 219,987 | 0.21% | 주식 |
| BAKER BROS. ADVISORS LP | $17,997,836 | 211,267 | 0.20% | 주식 |
| California Public Employees Retirement System | $17,979,520 | 211,052 | 0.20% | 주식 |
| Nicholas Investment Partners, LP | $17,810,758 | 209,071 | 0.20% | 주식 |
| PINNACLE ASSOCIATES LTD | $17,245,864 | 202,440 | 0.19% | 주식 |
| Mirador Capital Partners LP | $17,239,900 | 202,370 | 0.19% | 주식 |
| Tri Locum Partners LP | $16,526,860 | 194,000 | 0.18% | 주식 |
| PFM Health Sciences, LP | $16,329,730 | 191,686 | 0.18% | 주식 |
| Rock Springs Capital Management LP | $16,014,016 | 187,980 | 0.18% | 주식 |
| PRUDENTIAL FINANCIAL INC | $15,933,512 | 187,035 | 0.18% | 주식 |
| DAFNA Capital Management LLC | $14,652,510 | 171,998 | 0.16% | 주식 |
| Ghisallo Capital Management LLC | $14,482,300 | 170,000 | 0.16% | 주식 |
| Impax Asset Management Group plc | $14,056,350 | 165,000 | 0.16% | 주식 |
| Lombard Odier Asset Management (Europe) Ltd | $13,494,096 | 158,400 | 0.15% | 콜 옵션 |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | $13,383,349 | 157,100 | 0.15% | 주식 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $13,330,276 | 156,477 | 0.15% | 주식 |
| JANE STREET GROUP, LLC | $12,735,905 | 149,500 | 0.14% | 풋 옵션 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $12,145,719 | 139,190 | 0.14% | 주식 |
| Retirement Systems of Alabama | $11,962,891 | 140,426 | 0.13% | 주식 |
| MetLife Investment Management, LLC | $11,930,519 | 140,046 | 0.13% | 주식 |
| Polymer Capital Management (HK) LTD | $11,777,943 | 138,255 | 0.13% | 주식 |
| Cinctive Capital Management LP | $11,742,419 | 137,838 | 0.13% | 주식 |
| TUDOR INVESTMENT CORP ET AL | $11,279,156 | 132,400 | 0.13% | 콜 옵션 |
회사 내부자 52 명의 내부자 · 18 임원 · 22 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Sung Lee | EVP, Chief Financial Officer | 2026년 7월 1일 M | 63,221 | 0 | 5 | $-5,695,855 |
| Ching Jaw | SVP Finance & CFO | 2023년 3월 6일 A | 87,346 | 0 | 0 | $0 |
| Sharon Surrey Barbari | EVP, Finance & CFO | 2017년 2월 28일 F | 40,323 | 0 | 0 | $0 |
| Fady Ibraham Malik | EVP Research & Development | 2026년 8월 18일 M | 153,902 | 0 | 21 | $-4,352,750 |
| Andrew Callos | EVP, Chief Commercial Officer | 2026년 7월 30일 M | 58,555 | 0 | 24 | $-15,318,893 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | 2026년 3월 15일 A | 107,943 | 0 | 0 | $0 |
| Robert Wong | VP, Chief Accounting Officer | 2024년 12월 3일 A | 18,655 | 0 | 0 | $0 |
| Brett A Pletcher | EVP, Chief Legal Officer | 2024년 8월 30일 A | 33,140 | 0 | 0 | $0 |
| Mark A Schlossberg | SVP - Legal & General Counsel | 2022년 3월 15일 M | 103,408 | 0 | 0 | $0 |
| David Cragg | Chief HR & Admin Officer | 2022년 3월 7일 F | 153,233 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | GC & Chief Compliance Officer | 2018년 2월 27일 A | 32,548 | 0 | 0 | $0 |
| Peter S Roddy | SVP Finance & CAO | 2018년 2월 27일 A | 21,520 | 0 | 0 | $0 |
| Bradley Paul Morgan | SVP Drug Discovery & Early Dev | 2017년 8월 31일 M | 46,441 | 0 | 0 | $0 |
| Bonnie Charpentier | SVP Regulatory & Compliance | 2017년 2월 28일 A | 29,004 | 0 | 0 | $0 |
| Andrew A Wolff | SVP & CMO | 2017년 2월 28일 A | 47,255 | 0 | 0 | $0 |
| David J Morgans JR | EVP-Preclinical R&D | 2011년 2월 28일 A | 42,000 | 0 | 0 | $0 |
| Michael Rabson | SVP Business Dev/Legal & GC | 2009년 12월 18일 M | 20,043 | 0 | 0 | $0 |
| Jay K Trautman | VP, Discovery Research | 2008년 2월 29일 A | 47,896 | 0 | 0 | $0 |
| Robert Arthur Harrington | 이사 | 2026년 7월 15일 A | 21,932 | 0 | 2 | $-248,260 |
| James M Daly | 이사 | 2026년 7월 15일 A | 3,390 | 0 | 0 | $0 |
| Edward M. Kaye MD | 이사 | 2026년 7월 15일 A | 10,434 | 0 | 6 | $-3,544,372 |
| Nancy Wysenski | 이사 | 2026년 7월 15일 A | 33,992 | 0 | 0 | $0 |
| Wendell Wierenga | 이사 | 2026년 7월 15일 A | 35,563 | 0 | 3 | $-1,881,925 |
| John T Henderson | 이사 | 2026년 7월 15일 A | 78,360 | 0 | 2 | $-2,078,525 |
| Lynne B Parshall | 이사 | 2026년 6월 1일 S | 15,784 | 0 | 3 | $-1,000,100 |
| Muna Bhanji | 이사 | 2026년 5월 27일 A | 26,361 | 0 | 0 | $0 |
| Robert E Landry | 이사 | 2026년 5월 27일 A | 10,184 | 0 | 0 | $0 |
| Wendall Wierenga | 이사 | 2025년 7월 15일 A | 32,345 | 0 | 0 | $0 |
| COSTA SANTO J | 이사 | 2024년 5월 15일 A | 20,600 | 0 | 0 | $0 |
| Sandford D Smith | 이사 | 2024년 1월 2일 A | 18,801 | 0 | 0 | $0 |
| Robert Califf | 이사 | 2022년 1월 3일 A | 6,003 | 0 | 0 | $0 |
| GAGE L PATRICK | 이사 | 2021년 11월 8일 M | 28,932 | 0 | 0 | $0 |
| Denise Gilbert | 이사 | 2015년 5월 20일 J | — | 0 | 0 | $0 |
| Stephen M Dow | 이사 | 2013년 1월 2일 A | 1,421,052 | 0 | 0 | $0 |
| James A Spudich | 이사 | 2011년 5월 18일 A | 180,600 | 0 | 0 | $0 |
| Grant A Heidrich III | 이사 | 2011년 1월 3일 A | 93,755 | 0 | 0 | $0 |
| Michael Schmertzler | 이사 | 2010년 6월 3일 S | 4,340,923 | 0 | 0 | $0 |
| Mark Mcdade | 이사 | 2009년 5월 21일 A | — | 0 | 0 | $0 |
| Charles J Homcy | 이사 | 2008년 5월 22일 A | — | 0 | 0 | $0 |
| William J Rutter | 이사 | 2004년 4월 29일 C | 172,413 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VI LP | 10% 소유주 | 2004년 4월 29일 C | 1,615,716 | 0 | 0 | $0 |
| SRB ASSOCIATES VIII LP | 10% 소유주 | 2004년 4월 29일 C | 771,052 | 0 | 0 | $0 |
| SRB ASSOCIATES VII LP | 10% 소유주 | 2004년 4월 29일 C | 650,000 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VIII LP | 10% 소유주 | 2004년 4월 29일 C | 755,631 | 0 | 0 | $0 |
| Robert I Blum | — | 2026년 8월 10일 M | 377,820 | 0 | 19 | $-9,702,097 |
| Elisabeth Schnieders | — | 2017년 2월 28일 A | 43,919 | 0 | 0 | $0 |
| James H Sabry | — | 2010년 6월 3일 M | 0 | 0 | 0 | $0 |
| SEVIN ROSEN VII AFFILIATES FUND LP | — | 2004년 4월 29일 C | 24,050 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VII LP | — | 2004년 4월 29일 C | 625,950 | 0 | 0 | $0 |
| SRB ASSOCIATES VI LP | — | 2004년 4월 29일 C | 1,742,951 | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
ETF 보유 현황 84 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| LFSC · RBB Fund, Inc. | 3.16% | 43,268 NS | 2026년 5월 31일 | N-PORT |
| HRTS · Tema ETF Trust | 2.52% | 17,069 NS | 2026년 5월 31일 | N-PORT |
| FMED · Fidelity Covington Trust | 1.55% | 8,262 NS | 2026년 5월 31일 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 1.40% | 3,663 NS | 2026년 5월 31일 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1.24% | 189,801 NS | 2026년 4월 30일 | N-PORT |
| JSML · Janus Detroit Street Trust | 0.98% | 48,338 NS | 2026년 4월 30일 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.94% | 76,297 NS | 2026년 4월 30일 | N-PORT |
| BBC · ETFis Series Trust I | 0.75% | 4,355 NS | 2026년 4월 30일 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0.51% | 41,612 NS | 2026년 4월 30일 | N-PORT |
| BIB · ProShares Trust | 0.47% | 4,553 NS | 2026년 5월 31일 | N-PORT |
| NUSC · Nushares ETF Trust | 0.47% | 94,565 NS | 2026년 4월 30일 | N-PORT |
| MIDE · DBX ETF Trust | 0.41% | 178 NS | 2026년 5월 29일 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0.34% | 16,959 NS | 2026년 4월 30일 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0.26% | 55,086 NS | 2026년 4월 30일 | N-PORT |
| ITWO · ProShares Trust | 0.25% | 6,062 NS | 2026년 5월 31일 | N-PORT |
| RSSL · Global X Funds | 0.23% | 51,834 NS | 2026년 4월 30일 | N-PORT |
| PTMC · Pacer Funds Trust | 0.23% | 14,028 NS | 2026년 4월 30일 | N-PORT |
| MVV · ProShares Trust | 0.22% | 4,565 NS | 2026년 5월 31일 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0.21% | 635,330 NS | 2026년 5월 31일 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0.20% | 19,862 NS | 2026년 4월 30일 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0.19% | 356,940 NS | 2026년 5월 31일 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0.19% | 37,821 NS | 2026년 4월 30일 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0.15% | 2,025 NS | 2026년 4월 30일 | N-PORT |
| UMDD · ProShares Trust | 0.15% | 638 NS | 2026년 5월 31일 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.15% | 11,444 NS | 2026년 4월 30일 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0.15% | 47,609 NS | 2026년 4월 30일 | N-PORT |
| UWM · ProShares Trust | 0.15% | 4,765 NS | 2026년 5월 31일 | N-PORT |
| SMDX · Tidal Trust III | 0.15% | 2,868 NS | 2026년 4월 30일 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.12% | 53,720 NS | 2026년 4월 30일 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.12% | 154 NS | 2026년 5월 31일 | N-PORT |
| NBCR · Neuberger Berman ETF Trust | 0.10% | 12,090 NS | 2026년 5월 31일 | N-PORT |
| URTY · ProShares Trust | 0.10% | 4,793 NS | 2026년 5월 31일 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0.06% | 2,263 NS | 2026년 5월 31일 | N-PORT |
| FFLG · FIDELITY COVINGTON TRUST | 0.06% | 5,490 NS | 2026년 4월 30일 | N-PORT |
| ESLV · Strategy Shares | 0.05% | 100 NS | 2026년 4월 30일 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.05% | 4,582 NS | 2026년 5월 31일 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.05% | 5,851 NS | 2026년 5월 31일 | N-PORT |
| HDG · ProShares Trust | 0.04% | 121 NS | 2026년 5월 31일 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0.02% | 30,621 NS | 2026년 5월 31일 | N-PORT |
| TILT · FlexShares Trust | 0.02% | 5,462 NS | 2026년 4월 30일 | N-PORT |
| SCHK · SCHWAB STRATEGIC TRUST | 0.01% | 10,669 NS | 2026년 5월 31일 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0.01% | 78,165 NS | 2026년 5월 31일 | N-PORT |
| GUSA · Goldman Sachs ETF Trust II | 0.01% | 3,973 NS | 2026년 5월 31일 | N-PORT |
| AVSU · AMERICAN CENTURY ETF TRUST | 0.01% | 570 NS | 2026년 5월 31일 | N-PORT |
| AVLC · AMERICAN CENTURY ETF TRUST | 0.01% | 1,547 NS | 2026년 5월 31일 | N-PORT |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0.01% | 173 NS | 2026년 5월 31일 | N-PORT |
| FTLS · First Trust Exchange-Traded Fund III | -0.10% | -35,935 NS | 2026년 4월 30일 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 2026년 7월 15일 | 일간 |
| VB · VANGUARD INDEX FUNDS | — | — | 2026년 7월 15일 | 일간 |
| VBK · VANGUARD INDEX FUNDS | — | — | 2026년 7월 15일 | 일간 |